MA52643A - Anticorps se liant spécifiquement au tl1a - Google Patents

Anticorps se liant spécifiquement au tl1a

Info

Publication number
MA52643A
MA52643A MA052643A MA52643A MA52643A MA 52643 A MA52643 A MA 52643A MA 052643 A MA052643 A MA 052643A MA 52643 A MA52643 A MA 52643A MA 52643 A MA52643 A MA 52643A
Authority
MA
Morocco
Prior art keywords
tl1a
binding specifically
antibodies binding
antibodies
specifically
Prior art date
Application number
MA052643A
Other languages
English (en)
Inventor
Adam William Clarke
Bridget Ann Cooksey
Anthony G Doyle
Vanya Pande
Matthew Pollard
Lynn Dorothy Poulton
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MA52643A publication Critical patent/MA52643A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sorting Of Articles (AREA)
MA052643A 2015-09-18 2016-09-16 Anticorps se liant spécifiquement au tl1a MA52643A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562220442P 2015-09-18 2015-09-18

Publications (1)

Publication Number Publication Date
MA52643A true MA52643A (fr) 2021-03-24

Family

ID=57043002

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42825A MA42825B1 (fr) 2015-09-18 2016-09-16 Anticorps se liant spécifiquement à tl1a
MA052643A MA52643A (fr) 2015-09-18 2016-09-16 Anticorps se liant spécifiquement au tl1a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA42825A MA42825B1 (fr) 2015-09-18 2016-09-16 Anticorps se liant spécifiquement à tl1a

Country Status (33)

Country Link
US (4) US10138296B2 (fr)
EP (2) EP3693393A1 (fr)
JP (2) JP7013366B2 (fr)
KR (1) KR101998535B1 (fr)
CN (1) CN108137693B (fr)
AR (1) AR106055A1 (fr)
AU (2) AU2016323460B2 (fr)
BR (1) BR122021002400A8 (fr)
CA (1) CA2997015A1 (fr)
CL (1) CL2018000711A1 (fr)
CO (1) CO2018003736A2 (fr)
CY (1) CY1123499T1 (fr)
DK (1) DK3350223T3 (fr)
EA (1) EA201890756A1 (fr)
ES (1) ES2810751T3 (fr)
HR (1) HRP20201323T1 (fr)
HU (1) HUE051496T2 (fr)
IL (1) IL257761B2 (fr)
LT (1) LT3350223T (fr)
MA (2) MA42825B1 (fr)
MD (1) MD3350223T2 (fr)
MX (1) MX2018003185A (fr)
PE (1) PE20181080A1 (fr)
PH (1) PH12018500580B1 (fr)
PL (1) PL3350223T3 (fr)
PT (1) PT3350223T (fr)
RS (1) RS60703B1 (fr)
SI (1) SI3350223T1 (fr)
SM (1) SMT202000500T1 (fr)
TW (1) TWI703158B (fr)
UA (1) UA125284C2 (fr)
WO (1) WO2017049024A1 (fr)
ZA (1) ZA201801427B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
WO2017096358A1 (fr) * 2015-12-04 2017-06-08 University Of Iowa Research Foundation Appareil, systèmes et procédés de prédiction, de dépistage et de surveillance d'encéphalopathie/délire
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
KR20190082815A (ko) 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
AU2018259856B2 (en) * 2017-04-28 2025-05-01 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
NZ787680A (en) 2019-10-24 2026-02-27 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CN116348481A (zh) * 2020-08-19 2023-06-27 詹森生物科技公司 使用工程化配体的材料和方法
MX2023009681A (es) * 2021-02-18 2023-10-30 Prometheus Biosciences Inc Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
KR20250044336A (ko) 2022-07-27 2025-03-31 세파론 엘엘씨 궤양성 결장염 및 크론병의 치료를 위한 항-tl1a 항체
IL318297A (en) 2022-07-27 2025-03-01 Cephalon Llc Anti-TL1A antibody formulations
AU2024273758A1 (en) 2023-05-17 2025-12-04 Genentech, Inc. Anti-tl1a antibody therapeutic methods
EP4731660A2 (fr) * 2023-06-21 2026-04-29 Paragon Therapeutics, Inc. Compositions d'anticorps tl1a et procédés d'utilisation
CN121358765A (zh) * 2023-06-22 2026-01-16 派拉冈医疗公司 Il-23抗体组合物以及使用方法
WO2024263945A2 (fr) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Compositions d'anticorps ciblant l'il-17 et procédés d'utilisation
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US20250109209A1 (en) 2023-10-03 2025-04-03 Absci Corporation Tl1a associated antibody compositions and methods of use
CN120058933B (zh) * 2023-11-30 2026-02-10 北京智仁美博生物科技有限公司 抗肿瘤坏死因子样配体1a的抗体及其用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业（上海）股份有限公司 一种抗tl1a抗体及其制备方法和用途
WO2025170982A2 (fr) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Compositions d'anticorps anti-il-23 et méthodes d'utilisation
CN120590530A (zh) * 2024-03-05 2025-09-05 帆礼生物技术(武汉)有限公司 靶向tl1a的抗体及其应用
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
WO2026072993A1 (fr) 2024-09-27 2026-04-02 Genentech, Inc. Méthodes de traitement de la stéatohépatite associée à un dysfonctionnement métabolique avec un anticorps anti-tl1a
WO2026072983A1 (fr) 2024-09-27 2026-04-02 Genentech, Inc. Méthodes de traitement de la dermatite atopique avec un anticorps anti-tl1a
CN119552252B (zh) * 2025-01-16 2025-11-25 华润生物医药有限公司 抗tl1a抗体及其制备方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
WO2005018571A2 (fr) 2003-08-20 2005-03-03 University Of Miami Compositions et procedes pour le traitement de la maladie pulmonaire inflammatoire
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
US20090269345A1 (en) 2005-12-23 2009-10-29 Rong Fan CLN248 Antibody Compositions and Methods of Use
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
US20120073585A1 (en) 2009-04-08 2012-03-29 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
EP2519260A2 (fr) 2009-12-31 2012-11-07 Deutsches Krebsforschungszentrum Nouveaux modulateurs de signalisation par trail
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
WO2012161856A1 (fr) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blocage des interactions tl1a-dr3 pour améliorer la pathologie des maladies médiées par les cellules t et anticorps afférents
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014106602A1 (fr) 2013-01-02 2014-07-10 Glenmark Pharmaceuticals S.A. Anticorps qui se lient à tl1a et leurs utilisations
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
WO2014186665A2 (fr) 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Effets distincts d'ifn gamma et d'il-17 sur une inflammation et une fibrose modulées par tl1a
ES2894963T3 (es) 2013-05-17 2022-02-16 Cedars Sinai Medical Center Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
MX2016002879A (es) 2013-09-06 2016-08-17 Cedars Sinai Medical Center Sistemas, dispositivos y metodos para la terapia anti-tl1a.
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
EP3283499B1 (fr) 2015-04-15 2022-07-06 Biosearch Technologies, Inc. Sondes à désactivateur dual
JP2018522533A (ja) 2015-05-15 2018-08-16 シーダーズ—シナイ メディカル センター 炎症性腸疾患を処置するためのモデル、方法および組成物
EP3730188B1 (fr) 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions et procédés pour une utilisation en combinaison pour le traitement et le diagnostic de maladies auto-immunes
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US20180319889A1 (en) 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
MX392069B (es) 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN109219620B (zh) 2016-06-09 2023-01-31 派立卡恩治疗公司 抗-tnfrsf25抗体
KR20190082815A (ko) 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
WO2018195328A1 (fr) 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Procédés de prédiction de non-réponse à un traitement anti-tnf chez des sujets atteints d'une affection intestinale inflammatoire
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
PL3774897T3 (pl) 2018-04-30 2024-01-29 Cedars-Sinai Medical Center Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi
WO2020113116A1 (fr) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Procédés de classification et de traitement d'une sous-population de patients atteints d'une maladie intestinale inflammatoire
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
CA3162905A1 (fr) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Prediction de manifestations extra-intestinales de maladies intestinales inflammatoires
CA3180632A1 (fr) 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Methodes et systemes de mesure de la recurrence d'une maladie apres operation
WO2021247548A1 (fr) 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Traitements pour une sous-population de patients atteints d'une maladie intestinale inflammatoire
BR112022025667A2 (pt) 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
AU2021377688A1 (en) 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2022119842A1 (fr) 2020-12-01 2022-06-09 Cedars-Sinai Medical Center Procédés et systèmes pour stratification de patients atteints de maladie inflammatoire
WO2022140283A1 (fr) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Compositions thérapeutiques de tl1a et méthodes de traitement les utilisant
MX2023009681A (es) 2021-02-18 2023-10-30 Prometheus Biosciences Inc Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
TW202246322A (zh) 2021-02-18 2022-12-01 美商普羅米修斯生物科學股份有限公司 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
EP4330434A1 (fr) 2021-04-28 2024-03-06 Cedars-Sinai Medical Center Procédés et kits de sélection des patients pour thérapies ciblant tl1a
WO2023102051A1 (fr) 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Phagocytes mononucléaires intestinaux en tant que biomarqueur de pronostic pour la maladie de crohn
US20260000713A1 (en) 2021-12-01 2026-01-01 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
EP4460518A2 (fr) 2022-01-07 2024-11-13 Prometheus Biosciences, Inc. Méthodes de traitement de maladies inflammatoires avec combinaison d'inhibiteurs de tl1a et d'inhibiteurs d'il23
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof

Also Published As

Publication number Publication date
PE20181080A1 (es) 2018-07-05
US20170081400A1 (en) 2017-03-23
AU2016323460A1 (en) 2018-03-29
KR101998535B1 (ko) 2019-07-09
JP7341259B2 (ja) 2023-09-08
CN108137693B (zh) 2021-11-26
MA42825B1 (fr) 2020-09-30
CY1123499T1 (el) 2022-03-24
CA2997015A1 (fr) 2017-03-23
US11220549B2 (en) 2022-01-11
HK1256300A1 (zh) 2019-09-20
US20190106486A1 (en) 2019-04-11
LT3350223T (lt) 2020-10-26
IL257761B (en) 2022-11-01
BR122021002400A2 (fr) 2018-10-09
HK1251002A1 (en) 2019-01-18
BR122021002400A8 (pt) 2023-01-24
MX2018003185A (es) 2018-08-01
TWI703158B (zh) 2020-09-01
PH12018500580B1 (en) 2023-01-11
TW201722990A (zh) 2017-07-01
EP3350223A1 (fr) 2018-07-25
PH12018500580A1 (en) 2018-10-15
AU2016323460B2 (en) 2023-06-15
US20250179202A1 (en) 2025-06-05
WO2017049024A1 (fr) 2017-03-23
IL257761A (en) 2018-04-30
HUE051496T2 (hu) 2021-03-01
IL257761B2 (en) 2023-03-01
CN108137693A (zh) 2018-06-08
ZA201801427B (en) 2019-06-26
JP2018528773A (ja) 2018-10-04
JP7013366B2 (ja) 2022-02-15
US20220185902A1 (en) 2022-06-16
CL2018000711A1 (es) 2018-11-23
JP2022051771A (ja) 2022-04-01
DK3350223T3 (da) 2020-08-24
SI3350223T1 (sl) 2020-10-30
EP3693393A1 (fr) 2020-08-12
CO2018003736A2 (es) 2018-07-10
EA201890756A1 (ru) 2018-08-31
US10138296B2 (en) 2018-11-27
US12162946B2 (en) 2024-12-10
NZ740731A (en) 2024-07-26
AU2023203440A1 (en) 2023-06-29
BR112018005407A2 (en) 2018-10-09
HRP20201323T1 (hr) 2020-11-27
MD3350223T2 (ro) 2020-09-30
RS60703B1 (sr) 2020-09-30
SMT202000500T1 (it) 2020-11-10
EP3350223B1 (fr) 2020-06-17
UA125284C2 (uk) 2022-02-16
AR106055A1 (es) 2017-12-06
PL3350223T3 (pl) 2021-03-08
BR112018005407A8 (pt) 2023-01-24
KR20180048712A (ko) 2018-05-10
ES2810751T3 (es) 2021-03-09
AU2023203440B2 (en) 2026-04-16
PT3350223T (pt) 2020-08-05

Similar Documents

Publication Publication Date Title
MA52643A (fr) Anticorps se liant spécifiquement au tl1a
FR23C1036I1 (fr) Anticorps qui se lient à il-23
MA51734A (fr) Anticorps se liant à gprc5d
KR102355950B9 (ko) Tigit에 대한 항체
IL258909A (en) Antibodies specifically binding pd-1 and their uses
IL259173A (en) Ctla4 binders
MA46354A (fr) Molécules se liant spécifiquement au vph
EP3461261A4 (fr) Protéines se liant au fragment monocaténaire variable de cd3
MA42380A (fr) Anticorps se liant à tau
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
DK3242892T3 (da) Modificerede april-bindende antistoffer
PL3177644T3 (pl) Immunologiczne reagenty wiążące do PD-1
MA42377A (fr) Anticorps se liant à tau
HUE048667T2 (hu) AXL-hez kötõdõ ellenanyagok
DK3221363T3 (da) Antistoffer mod cd73 og anvendelser deraf
DK2970464T3 (da) Anti-lag-3-bindende proteiner
MA49289A (fr) Anticorps se liant à steap-1
IL263272A (en) Anti-coagulation factor xi antibodies
EP2949750A4 (fr) Peptide liant les anticorps
EP3375873A4 (fr) Polypeptide se liant aux immunoblobulines
MA51554A (fr) Anticorps il-6 améliorés
EP3349794A4 (fr) Anticorps anti-cd115
EP3297662A4 (fr) Anticorps se liant à des protéines axl